Ashiya Mona 4
4 · Shattuck Labs, Inc. · Filed Jun 15, 2026
Research Summary
AI-generated summary of this filing
Shattuck Labs (STTK) Director Ashiya Mona Acquires Shares in Offering
What Happened
- Ashiya Mona, a director of Shattuck Labs, reported purchases on June 11, 2026 totaling 1,250,000 securities (1,041,667 and 208,333 units). The Form 4 shows these as purchases (code P); the form lists price as N/A.
- Footnote to the filing explains these transactions were part of the company’s public offering that closed June 11, 2026: common shares were priced at $4.00 each and, in lieu of shares to certain investors, pre-funded warrants were sold at $3.9999 each. Based on the offering price, the 1,250,000 units equal roughly $5.0 million in aggregate consideration.
- This was a purchase (an acquisition), which investors often view as a more informative/“bullish” signal than sales, though no motive is stated.
Key Details
- Transaction date: June 11, 2026; Form 4 filed June 15, 2026 (appears timely).
- Reported items: two purchase entries — 1,041,667 and 208,333 units; Form shows price N/A, offering priced at $4.00/share or $3.9999/pre-funded warrant per footnote.
- Shares owned after transaction: not specified in the filing.
- Notable footnotes: (F1) these purchases were part of a public offering closed June 11; (F2) pre-funded warrants (if issued) are exercisable any time but subject to a 9.99% beneficial ownership blocker and expire once exercised.
- Filing timeliness: filed June 15 for a June 11 trade (within the typical two-business-day Form 4 window).
Context
- Pre-funded warrants: purchasers pay nearly full share value up front and later exercise the warrant (exercise price $0.0001 per share) to convert into common stock; the 9.99% blocker limits immediate conversion if it would push ownership above that threshold.
- The Form 4 does not break out how many of the units (if any) are common shares vs. pre-funded warrants; the footnotes provide the offering terms. No indications of sales, option exercises, gifts, or 10b5-1 plans are reported for these entries.
Insider Transaction Report
Form 4
Ashiya Mona
Director
Transactions
- Purchase
Pre-Funded Warrants (right to buy)
[F1][F2][F3][F5]2026-06-11+1,041,667→ 26,519,541 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (1,041,667 underlying) - Purchase
Pre-Funded Warrants (right to buy)
[F1][F2][F4][F5]2026-06-11+208,333→ 5,303,908 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (208,333 underlying)
Holdings
- 5,255,106(indirect: See Footnote)
Common Stock
[F3][F5] - 1,051,021(indirect: See Footnote)
Common Stock
[F4][F5]
Footnotes (5)
- [F1]On June 9, 2026, the Issuer announced a public offering of an aggregate of 10,879,376 shares of common stock ("Shares") at a price of $4.00 per Share and, in lieu of Shares to certain investors, pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 7,870,624 Shares at a price of $3.9999 per Pre-Funded Warrant. The Pre-Funded Warrant have an exercise price of $0.0001 per share and are exercisable at any time after the date of issuance. The public offering closed on June 11, 2026.
- [F2]The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full.
- [F3]These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX.
- [F4]These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
- [F5]Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Signature
/s/ Mona Ashiya|2026-06-15